Melanoma: Treatments and Resistance
نویسندگان
چکیده
منابع مشابه
Alternative treatments for melanoma: targeting BCL-2 family members to de-bulk and kill cancer stem cells
For the first time new treatments in melanoma have produced significant responses in advanced diseases, but 30-90% of melanoma patients do not respond or eventually relapse after the initial response to the current treatments. The resistance of these melanomas is likely due to tumor heterogeneity, which may be explained by models such as the stochastic, hierarchical, and phenotype-switching mod...
متن کاملAre there Relationships between the VDR-FokI Polymorphism and Vitamin D and the Insulin Resistance in Non-melanoma Skin Cancer (NMSC) Patients? A Protocol for Case-control Studies
Background and Objectives: Evidence indicate relationships between the sunlight exposure, vitamin D status and non-melanoma skin cancer (NMSC) risk. Vitamin D receptor (VDR) polymorphisms have been linked to metabolic changes in insulin resistance and various cancers. The purpose of this study is to investigate relationships between the sunlight exposure and the NMSC risk. Furthermore, relation...
متن کاملIncreased Cytotoxicity of Cisplatin in SK-MEL 28 Melanoma Cells upon Down-Regulation of Melanoma Inhibitor of Apoptosis Protein
Background: Malignant melanoma is a highly metastatic cutaneous cancer and typically refractory to chemotherapy. Deregulated apoptosis has been identified as a major cause of cancer drug resistance, and upregulated expression of the inhibitor of apoptosis protein melanom, an inhibitor of apoptosis (ML-IAP) is frequent in melanoma. Methods: Based on the conclusion that ML-IAP expression contribu...
متن کاملMultiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets
Molecular mechanisms involved in pathogenesis of malignant melanoma have been widely studied and novel therapeutic treatments developed in recent past years. Molecular targets for therapy have mostly been recognized in the RAS-RAF-MEK-ERK and PI3K-AKT signaling pathways; small-molecule inhibitors were drawn to specifically target key kinases. Unfortunately, these targeted drugs may display intr...
متن کاملUse of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells
MCL-1 (BCL-2 family anti-apoptotic protein) is responsible for melanoma's resistance to therapy. Cancer initiating cells also contribute to resistance and relapse from treatments. Here we examined the effects of the MCL-1 inhibitor SC-2001 in killing non melanoma-initiating-cells (bulk of melanoma), and melanoma-initiating-cells (MICs). By itself, SC-2001 significantly kills melanoma cells unde...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2017